scholarly journals Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (4) ◽  
pp. 497-503 ◽  
Author(s):  
Meletios A. Dimopoulos ◽  
Antonio Palumbo ◽  
Paolo Corradini ◽  
Michele Cavo ◽  
Michel Delforge ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Poor Prognosis ◽  
Low Dose ◽  
Standard Of Care ◽  
Safety And Efficacy ◽  
Refractory Multiple Myeloma ◽  
Key Points ◽  
Effective Treatments

Key Points STRATUS (MM-010), the largest POM + LoDEX trial, confirms the regimen offers clinically meaningful benefit and is generally well tolerated. STRATUS supports POM + LoDEX as a standard of care for patients with RRMM who have poor prognosis and high need for effective treatments.

scholarly journals Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (19) ◽  
pp. 2297-2306 ◽  
Author(s):  
Inger S. Nijhof ◽  
Laurens E. Franssen ◽  
Mark-David Levin ◽  
Gerard M. J. Bos ◽  
Annemiek Broijl ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.

scholarly journals Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Blood ◽  
2013 ◽  
Vol 121 (11) ◽  
pp. 1961-1967 ◽  
Author(s):  
Paul G. Richardson ◽  
David Siegel ◽  
Rachid Baz ◽  
Susan L. Kelley ◽  
Nikhil C. Munshi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Safety And Efficacy ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points Pomalidomide with/without dexamethasone has promising activity and manageable toxicity in relapsed and refractory multiple myeloma patients.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Blood ◽  
2013 ◽  
Vol 121 (11) ◽  
pp. 1968-1975 ◽  
Author(s):  
Xavier Leleu ◽  
Michel Attal ◽  
Bertrand Arnulf ◽  
Philippe Moreau ◽  
Catherine Traulle ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Current Data ◽  
Phase 3 ◽  
Refractory Multiple Myeloma ◽  
Highly Active ◽  
Key Points ◽  
End Stage

Key Points Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.

scholarly journals Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Blood ◽  
2014 ◽  
Vol 123 (12) ◽  
pp. 1826-1832 ◽  
Author(s):  
Paul G. Richardson ◽  
David S. Siegel ◽  
Ravi Vij ◽  
Craig C. Hofmeister ◽  
Rachid Baz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Option ◽  
Low Dose ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Key Points ◽  
New Treatment ◽  
Randomized Phase 2

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.

scholarly journals Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Blood ◽  
2018 ◽  
Vol 131 (8) ◽  
pp. 855-863 ◽  
Author(s):  
Christine Chen ◽  
David Siegel ◽  
Martin Gutierrez ◽  
Meagan Jacoby ◽  
Craig C. Hofmeister ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Safety And Efficacy ◽  
Waldenström Macroglobulinemia ◽  
Refractory Multiple Myeloma ◽  
Waldenstrom Macroglobulinemia ◽  
Key Points

Key Points Selinexor is an oral XPO1 inhibitor with antimyeloma activity. The RP2D is 45 mg/m2 (80 mg) selinexor plus 20 mg dexamethasone given twice weekly.

scholarly journals Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Blood ◽  
2017 ◽  
Vol 130 (10) ◽  
pp. 1189-1197 ◽  
Author(s):  
Ashraf Badros ◽  
Elizabeth Hyjek ◽  
Ning Ma ◽  
Alexander Lesokhin ◽  
Ahmet Dogan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Lymphocytes ◽  
Clinical Efficacy ◽  
Low Dose ◽  
Myeloma Cells ◽  
Refractory Multiple Myeloma ◽  
Key Points ◽  
Potential Biomarkers

Key Points This is the first trial to investigate PD-1 inhibitor, pembrolizumab, and an IMiD (pomalidomide) in MM with promising clinical efficacy. PD-L1 expression on myeloma cells and PD-1 on marrow infiltrating T lymphocytes are potential biomarkers for efficacy of PD-1 blockade.

Sign in / Sign up

Export Citation Format

Share Document